By 2030, antibiotic production will move to space. Orbital pharmaceutical stations will cultivate mutated bacteriophages in microgravity to create drugs that evade resistance. The lack of gravity alters bacterial interactions, allowing for the design of more effective bacteriophage viruses. This replaces terrestrial production and opens an orbital biotechnological race between laboratories and space agencies.
Microgravity and directed mutation 🧬
In space, bacteriophages show distinct mutation patterns. Without convection or sedimentation, bacterial colonies grow in three-dimensional structures, exposing more targets to phages. Orbital reactors apply controlled stress to force mutations in phages, selecting those that break bacterial resistance mechanisms. Each batch is analyzed in autonomous laboratory modules, sending data to Earth. Weekly production can exceed that of a terrestrial plant, using fewer resources and avoiding cross-contamination.
Pharmaceuticals in low orbit: the pharmacy of the future 🚀
Large pharmaceutical companies already rent space on stations as if they were offices in an industrial park, only with views of Earth and no possibility of ordering coffee. Investors debate whether the next big business will be curing infections or selling insurance against cosmic rays that damage crops. Meanwhile, astronauts complain that mutant bacteriophages smell worse than freeze-dried food. The space race is no longer about the Moon, but about the perfect dose.